Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E14.88 EPS (ttm)12.60 Insider Own0.10% Shs Outstand631.60M Perf Week0.44%
Market Cap118.43B Forward P/E12.60 EPS next Y14.88 Insider Trans-3.63% Shs Float631.32M Perf Month-6.98%
Income8.39B PEG7.44 EPS next Q3.48 Inst Own79.80% Short Float1.56% Perf Quarter-3.80%
Sales23.75B P/S4.99 EPS this Y14.80% Inst Trans-0.11% Short Ratio3.05 Perf Half Y-4.97%
Book/sh19.62 P/B9.56 EPS next Y5.99% ROA12.30% Target Price204.38 Perf Year2.78%
Cash/sh46.40 P/C4.04 EPS next 5Y2.00% ROE58.50% 52W Range163.31 - 210.19 Perf YTD-3.68%
Dividend5.80 P/FCF16.80 EPS past 5Y13.70% ROI19.60% 52W High-10.79% Beta1.21
Dividend %3.09% Quick Ratio2.60 Sales past 5Y4.90% Gross Margin82.70% 52W Low14.81% ATR3.54
Employees21500 Current Ratio2.80 Sales Q/Q7.40% Oper. Margin43.20% RSI (14)49.05 Volatility1.42% 1.88%
OptionableYes Debt/Eq2.71 EPS Q/Q18.80% Profit Margin35.30% Rel Volume0.85 Prev Close185.50
ShortableYes LT Debt/Eq2.36 EarningsJan 29 AMC Payout41.60% Avg Volume3.23M Price187.50
Recom2.30 SMA20-0.69% SMA50-2.39% SMA200-2.58% Volume2,756,995 Change1.08%
Jan-28-19Downgrade Evercore ISI Outperform → In-line
Oct-01-18Initiated Cantor Fitzgerald Neutral $223
Apr-05-18Reiterated Barclays Equal Weight $190 → $180
Feb-12-18Reiterated Mizuho Buy $192 → $200
Jan-23-18Upgrade Argus Hold → Buy
Nov-01-17Downgrade Argus Buy → Hold
Oct-26-17Reiterated RBC Capital Mkts Sector Perform $192 → $188
Sep-28-17Reiterated Mizuho Buy $183 → $198
Sep-15-17Initiated RBC Capital Mkts Sector Perform $192
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-22-19 04:53PM  Amgen Starts Phase III Enrollment for Heart Failure Drug Zacks
08:00AM  The Top 5 Biotech Stocks Are Facing Growth Challenges Are Any Immune? Investor's Business Daily
Feb-21-19 10:18PM  Cytokinetics Inc (CYTK) Q4 2018 Earnings Conference Call Transcript Motley Fool
09:24AM  The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion Zacks
09:12AM  Merck Gets Priority Review for Keytruda in Third-Line SCLC Zacks
08:30AM  Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure PR Newswire
08:30AM  Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure GlobeNewswire
Feb-20-19 02:23PM  Top Analyst Reports for Walmart, Amgen and Honda Zacks
12:18PM  AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review Zacks
08:39AM  Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study Zacks
Feb-19-19 04:41PM  Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review Zacks
Feb-18-19 08:10AM  Merck Gets Priority Review for Keytruda Combo in Kidney Cancer Zacks
Feb-17-19 02:23PM  Behind the Cutting Edge Technology: The History of Amgen
11:15AM  Is Amgen a Buy? Motley Fool
Feb-15-19 04:13PM  Amgen Inc. -- Moody's announces completion of a periodic review of ratings of Amgen Inc. Moody's
01:21PM  This Is One Company That Could Break Up Bristol-Celgene Deal Investor's Business Daily
08:01AM  [$$] WSJ Tax Guide 2019: The Drug Industry The Wall Street Journal
Feb-14-19 01:00PM  Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings Zacks
08:41AM  Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down Zacks
Feb-13-19 03:07PM  Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report Zacks
Feb-12-19 09:12AM  Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Zacks
09:11AM  AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma Zacks
08:56AM  Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60% Zacks
Feb-11-19 11:45AM  Regenerons 60% Price Cut Shows Heat Is Still on Drug Companies
07:18AM  Sanofi and Regeneron cut list price of cholesterol drug by 60 percent Reuters
07:00AM  Sanofi and Regeneron cut list price of cholesterol drug by 60 pct Reuters
06:11AM  2 Days Left To Cash In On Amgen Inc. (NASDAQ:AMGN) Dividend Simply Wall St.
Feb-08-19 08:03AM  Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View Zacks
Feb-07-19 05:52AM  Amgen Falls 3%
Feb-06-19 09:37AM  Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down Zacks
Feb-05-19 09:02AM  Roche Submits sBLA to FDA for Label Expansion of Kadcyla Zacks
Feb-04-19 09:50AM  Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy Zacks
08:48AM  Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod Zacks
Feb-03-19 10:09AM  The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs Benzinga
09:01AM  A War on High Drug Prices Could Boost Biosimilars Motley Fool
Feb-01-19 04:50PM  Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance Zacks
03:59PM  Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva Reuters
02:06PM  Why Amgen Should Buy Alexion Pharmaceuticals
08:00AM  Factors of Influence in 2019, Key Indicators and Opportunity within Marathon Oil, Accuray, United Natural Foods, Systemax, Amgen, and NewLink Genetics New Research Emphasizes Economic Growth GlobeNewswire
Jan-31-19 01:51PM  How 5 Goldman Stock Portfolios Are Racing Ahead of The Market Investopedia
12:48PM  Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y Zacks
Jan-30-19 06:04PM  3 Stocks Decline Wednesday
11:31AM  Stocks making the biggest moves midday: Tupperware, AT&T, Boeing, Apple & more CNBC
11:08AM  Biotech Giants Amgen and Biogen Fall on Earnings, Alzheimers News
08:46AM  Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid Zacks
08:12AM  The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Amgen and OncoCyte ACCESSWIRE
07:52AM  Stocks making the biggest moves premarket: Boeing, Apple, Alibaba, Tesla & more CNBC
07:23AM  Dow Jones Futures: Apple, AMD Drive Premarket Rally Investor's Business Daily
06:26AM  [$$] Stocks to Watch: Apple, AMD, eBay, Amgen, GameStop, Square The Wall Street Journal
06:02AM  Amgen Falls 6%
05:54AM  Amgen Falls 6%
05:40AM  Amgen Falls 6%
05:17AM  Amgen Falls 5%
05:15AM  Amgen Falls 5%
04:30AM  Edited Transcript of AMGN earnings conference call or presentation 29-Jan-19 10:00pm GMT Thomson Reuters StreetEvents
12:14AM  Amgen, Inc (AMGN) Q4 2018 Earnings Conference Call Transcript Motley Fool
Jan-29-19 07:21PM  Amgen Leaves Investors With Mixed Emotions Motley Fool
07:02PM  Amgen 2019 forecast falls short of expectations, shares dip Reuters
05:52PM  Amgen Stock Falls After Hours on Light Forecast Despite Good Quarterly Earnings
05:41PM  Stocks making the biggest moves after hours: Apple, Amgen, AMD and more CNBC
05:03PM  Amgen Tops Fourth-Quarter Forecasts, But Slides On Weak Outlook Investor's Business Daily
05:00PM  Amgen 2019 forecast falls short of expectations, shares dip Reuters
04:53PM  Amgen 2019 forecast falls short of expectations, shares dip Reuters
04:24PM  Amgen: 4Q Earnings Snapshot Associated Press
04:21PM  Amgen stock lower after earnings beat, lower guidance MarketWatch
04:09PM  Amgen falls 3% after 2019 outlook falls short CNBC
04:05PM  Amgen quarterly profit tops Street view, 2019 forecast falls short Reuters
04:01PM  Amgen Reports Fourth Quarter And Full Year 2018 Financial Results PR Newswire
11:06AM  Amgen Earnings, Revenue beat in Q4
09:41AM  Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips Zacks
07:25AM  The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive Benzinga
Jan-28-19 04:59PM  Biotech is breaking out. Here's what one analyst says to watch ahead of 3 key earnings reports CNBC
04:21PM  Amgen Slips on Analyst Downgrade
04:15PM  How Novartis Could Throw A Haymaker And Slam Amgen's Sales Investor's Business Daily
10:19AM  Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN Zacks
08:52AM  Amgen downgraded to in-line from outperform by Evercore ISI MarketWatch
04:45AM  Amgen Falls 3%
04:17AM  Amgen (AMGN) to Report Q4 Earnings: What's in the Cards? Zacks
Jan-27-19 04:07PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings Benzinga
Jan-25-19 03:43PM  Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen Reuters
10:34AM  AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down Zacks
09:43AM  Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III Zacks
07:38AM  The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug Benzinga
Jan-24-19 04:34PM  Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings? Zacks
04:30PM  Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results PR Newswire
04:00PM  Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events PR Newswire
02:00PM  deCODE Publishes the First Full Resolution Genetic Map of the Human Genome PR Newswire
11:17AM  Pfizer (PFE) to Report Q4 Earnings: What's in the Cards? Zacks
10:59AM  Healthcare ETFs in Focus Ahead of Q4 Earnings Zacks
10:51AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks
09:27AM  Allergan stock up 0.2% after Phase 1/3 trial of rituximab biosimilar meets primary endpoints MarketWatch
09:00AM  Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab PR Newswire
Jan-23-19 02:33PM  Better Buy: Amgen vs. Johnson & Johnson Motley Fool
10:48AM  5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks
09:12AM  Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks
Jan-22-19 09:00AM  European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia PR Newswire
Jan-21-19 12:30PM  Top Analyst Reports for Bank of America, Merck & Netflix Zacks
10:10AM  Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive? Zacks
07:50AM  What's in Store for Bristol-Myers (BMY) in Q4 Earnings? Zacks
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center; Provention Bio, Inc.; and Molecular Partners AG. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUGAR RONALD DDirectorFeb 07Option Exercise54.712,000109,42014,988Feb 11 09:27 PM
SUGAR RONALD DDirectorFeb 07Sale190.002,000380,00012,988Feb 11 09:27 PM
Jacks TylerDirectorDec 06Option Exercise82.6020,0001,652,00028,979Dec 10 08:46 PM
Jacks TylerDirectorDec 06Sale195.4120,0003,908,2328,979Dec 10 08:46 PM
Piacquad DavidSVP, Business DevelopmentNov 30Option Exercise54.696,500355,48545,128Dec 03 08:13 PM
Patton Cynthia MSVP & CCONov 29Option Exercise54.691,77797,18423,090Dec 03 08:11 PM
Patton Cynthia MSVP & CCONov 29Sale202.881,777360,52021,313Dec 03 08:11 PM
HENDERSON REBECCA MDirectorAug 10Option Exercise63.113,000189,33016,197Aug 14 08:29 PM
Harper Sean EEVP, Research & DevelopmentJul 16Sale195.711,525298,45856,082Jul 16 08:20 PM
Harper Sean EEVP, Research & DevelopmentJun 12Sale184.271,525281,01257,510Jun 12 07:07 PM
Harper Sean EEVP, Research & DevelopmentMay 14Sale174.101,525265,50359,035May 15 07:52 PM
Piacquad DavidSVP, Business DevelopmentMay 11Option Exercise54.7115,000820,65051,566May 15 07:55 PM
Harper Sean EEVP, Research & DevelopmentApr 12Sale172.681,525263,33756,788Apr 16 07:03 PM
Harper Sean EEVP, Research & DevelopmentMar 16Sale189.751,525289,36965,682Mar 19 08:52 PM